Our findings suggest that increased expression of PD1 and TIM3 leads to CD8+ T cell dysfunction and poor survival of the HCC patients, indicating a necessity to identify these HCC patients for additional therapeutic opportunities. This evidence concerns the gene CD8A and hepatocellular carcinoma.